Efficacy data of ICLUSIG (ponatinib) in CP-CML
Explore ICLUSIG efficacy in chronic phase chronic myeloid leukemia
Long-term efficacy data across two pivotal trials in heavily pretreated and TKI-resistant CP-CML patients.1-3
In the OPTIC 45 mg → 15 mg cohort, more than half of patients had a response by 5 years.2-4 In PACE, ICLUSIG provided durable, clinically meaningful responses in TKI-resistant CP-CML patients, including those with the T315I mutation.1
Ponatinib (ICLUSIG) is recommended as a treatment option by NCCN treatment guidelines for certain patients with T315I mutation.2,4